Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.
| Revenue (Most Recent Fiscal Year) | $0.07M |
| Net Income (Most Recent Fiscal Year) | $-9.16M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 26.21 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -147.18% |
| Return on Assets (Trailing 12 Months) | -104.98% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.51 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.51 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.02 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.40 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.08 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 8.48M |
| Free Float | 2.34M |
| Market Capitalization | $89.88M |
| Average Volume (Last 20 Days) | 7274.05 |
| Beta (Past 60 Months) | 2.53 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 72.41% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |